<?xml version='1.0' encoding='utf-8'?>
<document id="27435455"><sentence text="Unbound liver concentration is the true inhibitor concentration that determines cytochrome P450-mediated drug-drug interactions in rat liver." /><sentence text="1" /><sentence text="窶オn order to identify the best inhibitor concentration for the accurate prediction of magnitude of a hepatic cytochrome P450 (CYP)-mediated drug-drug interaction (DDI), the DDI between nifedipine, the CYP substrate probe, and fluconazole, ketoconazole, or ritonavir, the CYP inhibitors, in in situ rat liver perfusion system and rats were investigated"><entity charOffset="185-195" id="DDI-PubMed.27435455.s3.e0" text="nifedipine" /><entity charOffset="226-237" id="DDI-PubMed.27435455.s3.e1" text="fluconazole" /><entity charOffset="239-251" id="DDI-PubMed.27435455.s3.e2" text="ketoconazole" /><entity charOffset="256-265" id="DDI-PubMed.27435455.s3.e3" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.27435455.s3.e0" e2="DDI-PubMed.27435455.s3.e0" /><pair ddi="false" e1="DDI-PubMed.27435455.s3.e0" e2="DDI-PubMed.27435455.s3.e1" /><pair ddi="false" e1="DDI-PubMed.27435455.s3.e0" e2="DDI-PubMed.27435455.s3.e2" /><pair ddi="false" e1="DDI-PubMed.27435455.s3.e0" e2="DDI-PubMed.27435455.s3.e3" /><pair ddi="false" e1="DDI-PubMed.27435455.s3.e1" e2="DDI-PubMed.27435455.s3.e1" /><pair ddi="false" e1="DDI-PubMed.27435455.s3.e1" e2="DDI-PubMed.27435455.s3.e2" /><pair ddi="false" e1="DDI-PubMed.27435455.s3.e1" e2="DDI-PubMed.27435455.s3.e3" /><pair ddi="false" e1="DDI-PubMed.27435455.s3.e2" e2="DDI-PubMed.27435455.s3.e2" /><pair ddi="false" e1="DDI-PubMed.27435455.s3.e2" e2="DDI-PubMed.27435455.s3.e3" /></sentence><sentence text=" 2" /><sentence text="窶オn in situ system, the intrinsic clearance (CLint) of nifedipine was decreased after co-infusion of the CYP inhibitors"><entity charOffset="55-65" id="DDI-PubMed.27435455.s5.e0" text="nifedipine" /></sentence><sentence text=" The decrease in in situ CLint of nifedipine was most comparable to that in in vitro CLint in rat liver microsomes calculated by using the unbound liver concentrations of inhibitors ([I]liver,u)"><entity charOffset="34-44" id="DDI-PubMed.27435455.s6.e0" text="nifedipine" /></sentence><sentence text=" The ratios of unbound liver concentration to unbound hepatic vein concentration (Kp,uu) of ketoconazole and ritonavir were 4"><entity charOffset="92-104" id="DDI-PubMed.27435455.s7.e0" text="ketoconazole" /><entity charOffset="109-118" id="DDI-PubMed.27435455.s7.e1" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.27435455.s7.e0" e2="DDI-PubMed.27435455.s7.e0" /><pair ddi="false" e1="DDI-PubMed.27435455.s7.e0" e2="DDI-PubMed.27435455.s7.e1" /></sentence><sentence text="0-8" /><sentence text="0 and 18" /><sentence text="4-21" /><sentence text="1, suggesting a concentrative uptake of them into liver" /><sentence text=" 3" /><sentence text="窶オn rats, the DDI effects of orally administered nifedipine with constant infusion of the inhibitors were investigated"><entity charOffset="49-59" id="DDI-PubMed.27435455.s13.e0" text="nifedipine" /></sentence><sentence text=" The most accurate prediction of magnitude of DDI was achieved when [I]liver,u was applied as the inhibitor concentration" /><sentence text=" 4" /><sentence text="窶サhese results indicated that [I]liver,u is the most reliable inhibitor concentration for CYP-mediated DDI and it is necessary to consider the concentrative uptake of inhibitors into liver for the quantitative prediction of DDI" /><sentence text="" /></document>